Moleculin Biotech, Inc., incorporated on July 28, 2015, is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. The Company's lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline. Annamycin is a liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms.
The Company has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. In vitro testing has shown a high level of activity for WP1066 against a range of solid tumors, and in vivo testing has shown significant activity against head and neck, pancreatic, stomach and ovarian cancers, as well as metastatic melanoma and glioblastoma, among others. In vivo testing in mouse tumor models has shown that WP1066 inhibits tumor growth, blocks angiogenesis (a process that provides necessary blood supply to tumors) and increases survival. As of September 30, 2016, the Company had not generated any revenue from its operations.
2575 W Bellfort Ave Ste 333
The company trades on NASDAQ exchange. The company headquarter is located in Texas, TX. The company was established in the 2015.| Ticker | MBRX |
| Long Name | Moleculin Biotech, Inc. |
| Short Name | Moleculin Biotech |